UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Synergistic Cancer Therapeutic Effects of Locally Delivered Drug and Heat Using Multifunctional Nanoparticles

Advanced materials (Weinheim), 2010-09, Vol.22 (36), p.4049-4053

2010

Volltextzugriff (PDF)

Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era

Hepatology research, 2022-03, Vol.52 (3), p.247-254

2022

Volltextzugriff (PDF)

Convertible Organic Nanoparticles for Near-Infrared Photothermal Ablation of Cancer Cells

Angewandte Chemie (International ed.), 2011-01, Vol.50 (2), p.441-444

International ed. in English, 2011

Volltextzugriff (PDF)

Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients

Clinical gastroenterology and hepatology, 2023-04, Vol.21 (4), p.1013-1022.e6

2023

Volltextzugriff (PDF)

A survey on the awareness, current management, and barriers for non-alcoholic fatty liver disease among the general Korean population

Scientific reports, 2023-09, Vol.13 (1), p.15205-8, Article 15205

2023

Volltextzugriff (PDF)

Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort

Gut and Liver, 2024, 18(2), , pp.316-327

2024

Volltextzugriff (PDF)

Comparative evaluation of non-invasive tests for risk stratification for cause specific mortality in at-risk population of hepatic fibrosis

Scientific reports, 2024-03, Vol.14 (1), p.7189-7189, Article 7189

2024

Volltextzugriff (PDF)

Multifunctional Nanoparticles for Photothermally Controlled Drug Delivery and Magnetic Resonance Imaging Enhancement

Small (Weinheim an der Bergstrasse, Germany), 2008-02, Vol.4 (2), p.192-196

2008

Volltextzugriff (PDF)

Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population

Journal of clinical medicine, 2020-04, Vol.9 (4), p.1119

2020

Volltextzugriff (PDF)

A Critical Appraisal of the Definition of Sarcopenia in Patients with Non-Alcoholic Fatty Liver Disease: Pitfall of Adjusted Muscle Mass by Body Weight

Life (Basel, Switzerland), 2020-09, Vol.10 (10), p.218

2020

Volltextzugriff (PDF)

New sequential algorithm using Mac-2 binding protein glycosylation isomer to detect advanced carotid artery atherosclerosis

Annals of translational medicine, 2021-04, Vol.9 (7), p.566-566

2021

Volltextzugriff (PDF)

Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population

Frontiers in medicine, 2022-11, Vol.9, p.1024836-1024836

2022

Volltextzugriff (PDF)

Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea

Journal of clinical medicine, 2022-03, Vol.11 (6), p.1474

2022

Volltextzugriff (PDF)

Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver

Journal of clinical medicine, 2021-10, Vol.10 (19), p.4625

2021

Volltextzugriff (PDF)

Reply

Clinical gastroenterology and hepatology, 2023-04, Vol.21 (4), p.1115-1116

2023

Volltextzugriff (PDF)

Reply

Clinical gastroenterology and hepatology, 2023-03, Vol.21 (3), p.858-859

2023

Volltextzugriff (PDF)

Multifunctional Nanoparticles for Combined Doxorubicin and Photothermal Treatments

ACS nano, 2009-10, Vol.3 (10), p.2919-2926

2009

Volltextzugriff (PDF)

Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease

Gut, 2022-05, Vol.71 (5), p.1035-1036

2022

Volltextzugriff (PDF)

Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy

Clinical gastroenterology and hepatology, 2023-04, Vol.21 (4), p.1041-1049.e3

2023

Volltextzugriff (PDF)

SAT-284 Diagnostic performance of non-invasive tests in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with increased alcohol intake (MetALD) in a primary care setting

Journal of hepatology, 2024-06, Vol.80, p.S148-S148

2024

Volltextzugriff (PDF)

Letter to the Editor: Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional second-tier test?

Hepatology (Baltimore, Md.), 2023-09, Vol.78 (3), p.E59-E60

2023

Volltextzugriff (PDF)

FRI-223 Cost-effectiveness of one-time screening for advanced hepatic fibrosis using FIB-4 based two-step algorithm in the general population

Journal of hepatology, 2024-06, Vol.80, p.S473-S473

2024

Volltextzugriff (PDF)

WED-323 Diagnostic performances of FIB-4 and NFS in metabolic dysfunction-associated steatotic liver disease in primary care clinic of Asia

Journal of hepatology, 2024-06, Vol.80, p.S553-S553

2024

Volltextzugriff (PDF)

SAT-465 Increasing awareness among primary care physicians about MASLD reduced unnecessary referral rates and an increased cardiovascular evaluation

Journal of hepatology, 2024-06, Vol.80, p.S654-S654

2024

Volltextzugriff (PDF)

SAT-296 Prevalence and characteristics of MASLD with greater alcohol consumption (MetALD) in the general population

Journal of hepatology, 2024-06, Vol.80, p.S152-S152

2024

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(69)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Synergistic Cancer Therapeutic Effects of Locally Delivered Drug and Heat Using Multifunctional Nanoparticles

Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era

Convertible Organic Nanoparticles for Near-Infrared Photothermal Ablation of Cancer Cells

Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients

A survey on the awareness, current management, and barriers for non-alcoholic fatty liver disease among the general Korean population

Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort

Comparative evaluation of non-invasive tests for risk stratification for cause specific mortality in at-risk population of hepatic fibrosis

Multifunctional Nanoparticles for Photothermally Controlled Drug Delivery and Magnetic Resonance Imaging Enhancement

Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population

A Critical Appraisal of the Definition of Sarcopenia in Patients with Non-Alcoholic Fatty Liver Disease: Pitfall of Adjusted Muscle Mass by Body Weight

New sequential algorithm using Mac-2 binding protein glycosylation isomer to detect advanced carotid artery atherosclerosis

Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population

Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea

Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver

Reply

Reply

Multifunctional Nanoparticles for Combined Doxorubicin and Photothermal Treatments

Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease

Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy

SAT-284 Diagnostic performance of non-invasive tests in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with increased alcohol intake (MetALD) in a primary care setting

Letter to the Editor: Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional second-tier test?

FRI-223 Cost-effectiveness of one-time screening for advanced hepatic fibrosis using FIB-4 based two-step algorithm in the general population

WED-323 Diagnostic performances of FIB-4 and NFS in metabolic dysfunction-associated steatotic liver disease in primary care clinic of Asia

SAT-465 Increasing awareness among primary care physicians about MASLD reduced unnecessary referral rates and an increased cardiovascular evaluation

SAT-296 Prevalence and characteristics of MASLD with greater alcohol consumption (MetALD) in the general population

Suchergebnisse filtern